KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EPS (Basic) (2018 - 2025)

Historic EPS (Basic) for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$0.02.

  • Castle Biosciences' EPS (Basic) fell 12500.0% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.41, marking a year-over-year decrease of 28636.36%. This contributed to the annual value of $0.66 for FY2024, which is 13069.45% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' EPS (Basic) is -$0.02, which was down 12500.0% from $0.16 recorded in Q2 2025.
  • Castle Biosciences' 5-year EPS (Basic) high stood at $0.35 for Q4 2024, and its period low was -$1.1 during Q1 2023.
  • For the 5-year period, Castle Biosciences' EPS (Basic) averaged around -$0.32, with its median value being -$0.25 (2021).
  • Per our database at Business Quant, Castle Biosciences' EPS (Basic) plummeted by 106666.67% in 2023 and then skyrocketed by 48362.46% in 2024.
  • Castle Biosciences' EPS (Basic) (Quarter) stood at -$0.25 in 2021, then tumbled by 216.0% to -$0.79 in 2022, then soared by 88.61% to -$0.09 in 2023, then soared by 483.62% to $0.35 in 2024, then crashed by 105.79% to -$0.02 in 2025.
  • Its EPS (Basic) was -$0.02 in Q3 2025, compared to $0.16 in Q2 2025 and -$0.9 in Q1 2025.